Investigational Drug Details
| Drug ID: | D187 |
| Drug Name: | Ipragliflozin |
| Synonyms: | Ipragliflozin |
| Type: | Chemical drug |
| DrugBank ID: | DB11698 |
| DrugBank Description: | Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. |
| PubChem ID: | 10453870 |
| CasNo: | 761423-87-4 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)c1cc(Cc2cc3c(s2)cccc3)c(cc1)F |
| Structure: |
|
| InChiKey: | AHFWIQIYAXSLBA-RQXATKFSSA-N |
| Molecular Weight: | 404.459 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SGLT2 inhibitor |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 3 completed (JPRN-jRCTs071180069: A total of 55 patients were included in the current study. In the 51 patients (ipragliflozin=25, control=26) without discontinuation, decrease in HbA1c of ipragliflozin group at 72-week from baseline was not significantly different comparing with the control group. Body weight of ipragliflozin group decreased from baseline significantly more than control group. Patients with improvement of liver fibrosis was significantly more frequent n the ipragliflozin group than the control group.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0068 | NCT02875821 | Phase 4 | Completed | No Results Available | April 26, 2016 | June 23, 2017 | Details |
| L0472 | JPRN-jRCTs071180069 | Phase 3 | Not Recruiting | Has Results | 20/03/2019 | 20 April 2020 | Details |
| L0581 | JPRN-UMIN000022651 | Not selected | Not Recruiting | No Results Available | 07/06/2016 | 2 April 2019 | Details |
| L0888 | JPRN-UMIN000015727 | Not selected | Not Recruiting | No Results Available | 24/11/2014 | 3 December 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | Details |
| A04857 | 33479589 | Diabetol Int | Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report. | Details |
| A05042 | 33396949 | Metabolites | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | Details |
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | Details |
| A09056 | 31888083 | Int J Mol Sci | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. | Details |
| A09349 | 31782258 | Physiol Rep | SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. | Details |
| A12555 | 30393249 | Endocr J | Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results). | Details |
| A12902 | 30234161 | Open Med (Wars) | Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. | Details |
| A15414 | 28924123 | Intern Med | The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. | Details |
| A15703 | 28751548 | Diabetes Care | Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | Details |
| A17124 | 27980239 | Endocr J | Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. | Details |
| A18736 | 26977813 | PLoS One | Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. | Details |
| A18829 | 26914659 | Clin Drug Investig | Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. | Details |
| A19142 | 26731267 | PLoS One | The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. | Details |
| A20839 | 25701721 | Eur J Pharmacol | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. | Details |
| A28645 | 35192632 | PLoS One | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. | Details |
| A31250 | 30962742 | Yonago Acta Med | Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model. | Details |